Can BCR/ABL breakpoint fusion peptides be used as a target for GVL immunotherapy by expanding peptide specific T cells in patients in vivo?

Tools

Rusakiewicz, S., Dodi, I.A., Loconto, J., Travers, P.J. and Madrigal, J.A., 2004. Can BCR/ABL breakpoint fusion peptides be used as a target for GVL immunotherapy by expanding peptide specific T cells in patients in vivo? Blood Cells Molecules and Diseases, 33 (3), p. 191. ISSN 1079-9796

Full text not available from this repository.

Item Type:	Journal article
Publication Title:	Blood Cells Molecules and Diseases
Creators:	Rusakiewicz, S., Dodi, I.A., Loconto, J., Travers, P.J. and Madrigal, J.A.
Date:	2004
Volume:	33
Number:	3
ISSN:	1079-9796
Divisions:	Schools > School of Science and Technology
Record created by:	EPrints Services
Date Added:	09 Oct 2015 10:06
Last Modified:	19 Oct 2015 14:27
URI:	https://irep.ntu.ac.uk/id/eprint/7819